A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.

Patrick M BolandChristos FountzilasMarwan FakihMateusz OpyrchalJennifer R DiamondBradley CorrWen Wee MaMichelle RedmanWing-Kai ChanHui WangDoug KramerRudolf KwanDavid CutlerJay ZhiAntonio Jimeno

Published in: Cancer chemotherapy and pharmacology (2022)

dose levels. The safety profile of oratecan was comparable to that of intravenous irinotecan.

Keyphrases

open label
high dose
clinical trial
low dose
double blind